A new paper has been published this week by our team member Pavel Zhurauski in collaboration with scientists from the Universities of Bath, Leeds and the company Avacta Life Science Ltd. The publication is released in the journal Biosensors & Bioelectronics, demonstrates the application of Affimer binders to biosensors for use within potential clinical diagnostics. Affimer reagents, targeted to Her4, were immobilised upon an electrochemical sensor to form an Affimer-based biosensor for the detection of Her4. Characterisation of the Affimer-sensor revealed excellent target sensitivity in undiluted human serum across an extensive dynamic range, being able to accurately quantify Her4 concentration between 1 pM and 100 nM, with no observable matrix effect.
In this study, the researchers used electrochemical impedance sensors (EIS), which have recently gained attention as they offer label-free, fast and sensitive measurement with the possibility of miniaturised biosensor development. These sensors measure the changes in impedance or capacitance that occur at an electrode surface through binding of the target protein to an immobilised capture protein, in this instance an anti-Her4 Affimer binder.; their benefits include concentration detection over a wide range, their low cost, rapid kinetics, and suitability for point-of-care diagnostics.
Zimmer and Peacock Ltd is delighted to provide support in consulting, manufacturing and commercialisation of biosensors and point-of-care medical diagnostic technologies.
Please always feel free to ask us any question about our products and services. Our friendly team will try to find the best possible solution for your requirements!
